Literature DB >> 911609

Increased oxidation of phenylbutazone during hydrocortisone infusion in man.

J Aarbakke, M R Bending, D S Davies.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 911609      PMCID: PMC1429144          DOI: 10.1111/j.1365-2125.1977.tb00796.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  3 in total

1.  A STUDY OF STRUCTURE--ACTIVITY RELATIONSHIPS IN REGARD TO SPECIES DIFFERENCE IN THE PHENYLBUTAZONE SERIES.

Authors:  J M PEREL; M M SNELL; W CHEN; P G DAYTON
Journal:  Biochem Pharmacol       Date:  1964-09       Impact factor: 5.858

2.  Disposition and oxidative metabolism of phenylbutazone in man.

Authors:  J Aarbakke; O M Bakke; E J Milde; D S Davies
Journal:  Eur J Clin Pharmacol       Date:  1977       Impact factor: 2.953

3.  Immediate decrease by hydrocortisone of the plasma half-life of antipyrine.

Authors:  A Breckenridge; C W Burke; D S Davies; M L Orme
Journal:  Br J Pharmacol       Date:  1973-02       Impact factor: 8.739

  3 in total
  5 in total

Review 1.  Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs.

Authors:  R K Verbeeck
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

2.  Single-dose and steady-state pharmacokinetics of aminoglutethimide.

Authors:  P E Lønning; J S Schanche; S Kvinnsland; P M Ueland
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

3.  Dose dependent pharmacokinetics of prednisone and prednisolone in man.

Authors:  J Q Rose; A M Yurchak; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1981-08

Review 4.  Clinical pharmacokinetics and endocrine disorders. Therapeutic implications.

Authors:  P O'Connor; J Feely
Journal:  Clin Pharmacokinet       Date:  1987-12       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of phenylbutazone.

Authors:  J Aarbakke
Journal:  Clin Pharmacokinet       Date:  1978 Sep-Oct       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.